For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Please note control lysates are NOT included in the kits. Control lysates are sold separately, catalog number TRF4002S.
LANCE® and LANCE® (Lanthanide chelate excite) Ultra are homogeneous (no wash) TR-FRET (time-resolved fluorescence resonance energy transfer) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second antibody is labeled with an acceptor fluorophore [ULight™ dye]. Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm. Data are represented as ratiometric (665/615 nm X 10,000).
AKT, also known as protein kinase B, is an important regulator of numerous cellular processes including cell survival, glucose metabolism, transcription, and apoptosis. AKT has three closely related isoforms (AKT1, AKT2, and AKT3), and these isoforms have been shown to act on both common and unique downstream substrates. AKT activation can be induced by a number of stimuli, whereby AKT is transported to membrane for phosphorylation. Activation occurs upon AKT phosphorylation of Thr308 by PDK1 and of Ser473 by mTORC2. AKT subsequently dissociates from the membrane and phosphorylates targets both in the cytoplasm, as well as, the cell nucleus. Deregulation of AKT has been implicated in a number of disease states including cancer, cardiovascular disease, and diabetes.
|Assay Target Class||Phosphoprotein|
|Detection Method||Time-Resolved Fluorescence (TRF), TR-FRET|
|Product Brand Name||LANCE Ultra|
|Shipping Condition||Blue Ice|
|Unit Size||500 Assay Points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.